Brazil: 2016 clinical trials activity at lowest point in five years


Figure 1: Five-year historical trends in clinical trials in Brazil by phase, 2012-2016

As part of our series of white papers tracking clinical trials activity in emerging markets, GlobalData covered Brazil in December 2016. GlobalData captured records of 1,580 clinical trials across all diseases and phases that had a start date between 2012 and 2016 with at least one clinical site location in Brazil. The total number of trials decreased by 34% over the five-year period (see Figure 1).

Phase III trials largely predominant across the five years

For the purposes of the analysis depicted in Figure 1, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. The contribution of Phase I clinical trials started and ended the five-year period at 1%, with increases to 8% and 5% in 2013 and 2014 respectively. The percentage of Phase II trials decreased between 2012 and 2016 from 30% to 27%. Phase III trials took over the largest share of contribution at 56% by 2016. Phase IV clinical trials’ contribution remained overall flat from 17% to 16% between 2012 and 2016.